|
Hernández-Romero D, Ruiz-Nodar JM, Marín F, Tello-Montoliu A, Roldán V, Mainar L, Pérez-Andreu V, Antón AI, Bonaque JC, Valdés M, Vicente V, González-Conejero R. CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. Ann Med. 2010 Sep;42(6):439-46. doi: 10.3109/07853890.2010.499131. PubMed PMID: 20673165.
AÑO: 2010; IF: 4.323
|
20673165
|
López-Cuenca A, Marín F, Roldán V, Climent VE, Valdés M, Lip GY. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease. Int J Cardiol. 2010 Feb 18;139(1):95-7. doi: 10.1016/j.ijcard.2008.06.076. Epub 2008 Aug 22. PubMed PMID: 18722681.
AÑO: 2010; IF: 6.802
|
|
Jerez A, Fernández A, Osma MM, Roldán V, Ortuño FJ, Vicente V. Measuring the prognostic impact of ferritin levels in myelodysplastic syndrome patients: the role of susceptibility biases. Leukemia. 2010 Mar;24(3):640-2. doi: 10.1038/leu.2009.229. Epub 2009 Nov 5. PubMed PMID: 19890376.
AÑO: 2010; IF: 8.966
|
|
López-Cuenca A, Marín F, Roldán V, González-Conejero R, Hernández-Romero D, Valdés M, Lip GY. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Ann Med. 2010 Dec;42(8):562-75. doi: 10.3109/07853890.2010.507601. Epub 2010 Aug 4. Review. PubMed PMID: 20681943.
AÑO: 2010; IF: 4.323
|
|
Tello-Montoliu A, Marín F, Roldán V, Lip GY. The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage? Heart. 2010 Feb;96(3):227-8; author reply 228. doi: 10.1136/hrt.2009.182105. PubMed PMID: 20133421.
AÑO: 2010; IF: 4.708
|